COMPANION ANIMAL TREATMENTS
Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release mo...
Gespeichert in:
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | SHUKOOR, Mohammed I MORGAN, Michael E VARTY, Geoffrey B DRYSDALE, Doug PALFREYMAN, Michael NIVOROZHKIN, Alex AVERY, Kenneth L FENG, Ju PATHARE, Pradip M |
description | Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders.
L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024251807A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024251807A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024251807A13</originalsourceid><addsrcrecordid>eNrjZJB29vcNcPTz9PdTAJK-jj4KIUGujiG-rn4hwTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jAyMTI1NDCwNzR0Jg4VQDehSGN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPANION ANIMAL TREATMENTS</title><source>esp@cenet</source><creator>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</creator><creatorcontrib>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</creatorcontrib><description>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders.
L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241212&DB=EPODOC&CC=WO&NR=2024251807A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241212&DB=EPODOC&CC=WO&NR=2024251807A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHUKOOR, Mohammed I</creatorcontrib><creatorcontrib>MORGAN, Michael E</creatorcontrib><creatorcontrib>VARTY, Geoffrey B</creatorcontrib><creatorcontrib>DRYSDALE, Doug</creatorcontrib><creatorcontrib>PALFREYMAN, Michael</creatorcontrib><creatorcontrib>NIVOROZHKIN, Alex</creatorcontrib><creatorcontrib>AVERY, Kenneth L</creatorcontrib><creatorcontrib>FENG, Ju</creatorcontrib><creatorcontrib>PATHARE, Pradip M</creatorcontrib><title>COMPANION ANIMAL TREATMENTS</title><description>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders.
L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB29vcNcPTz9PdTAJK-jj4KIUGujiG-rn4hwTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jAyMTI1NDCwNzR0Jg4VQDehSGN</recordid><startdate>20241212</startdate><enddate>20241212</enddate><creator>SHUKOOR, Mohammed I</creator><creator>MORGAN, Michael E</creator><creator>VARTY, Geoffrey B</creator><creator>DRYSDALE, Doug</creator><creator>PALFREYMAN, Michael</creator><creator>NIVOROZHKIN, Alex</creator><creator>AVERY, Kenneth L</creator><creator>FENG, Ju</creator><creator>PATHARE, Pradip M</creator><scope>EVB</scope></search><sort><creationdate>20241212</creationdate><title>COMPANION ANIMAL TREATMENTS</title><author>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024251807A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHUKOOR, Mohammed I</creatorcontrib><creatorcontrib>MORGAN, Michael E</creatorcontrib><creatorcontrib>VARTY, Geoffrey B</creatorcontrib><creatorcontrib>DRYSDALE, Doug</creatorcontrib><creatorcontrib>PALFREYMAN, Michael</creatorcontrib><creatorcontrib>NIVOROZHKIN, Alex</creatorcontrib><creatorcontrib>AVERY, Kenneth L</creatorcontrib><creatorcontrib>FENG, Ju</creatorcontrib><creatorcontrib>PATHARE, Pradip M</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHUKOOR, Mohammed I</au><au>MORGAN, Michael E</au><au>VARTY, Geoffrey B</au><au>DRYSDALE, Doug</au><au>PALFREYMAN, Michael</au><au>NIVOROZHKIN, Alex</au><au>AVERY, Kenneth L</au><au>FENG, Ju</au><au>PATHARE, Pradip M</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPANION ANIMAL TREATMENTS</title><date>2024-12-12</date><risdate>2024</risdate><abstract>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders.
L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre |
recordid | cdi_epo_espacenet_WO2024251807A1 |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | COMPANION ANIMAL TREATMENTS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A22%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHUKOOR,%20Mohammed%20I&rft.date=2024-12-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024251807A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |